• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

POIESIS Trial Explores Navtemadlin Plus Jakafi for Myelofibrosis

by MM360 Staff | May 5, 2025 | Uncategorized

Source: CureToday articles The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis. Read More

My Lung Cancer Journey: With Family, Friends and Medical Professionals

by MM360 Staff | May 5, 2025 | Uncategorized

Source: CureToday articles The strongest connections I’ve made are with others who have also been through their own cancer journeys. Read More

AI Tool Predicts Pediatric Glioma Recurrence With Up to 89% Accuracy

by MM360 Staff | May 5, 2025 | Uncategorized

Source: CureToday articles An AI model using serial brain scans predicted glioma recurrence in children with up to 89% accuracy, outperforming single-image methods. Read More

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

by MM360 Staff | May 5, 2025 | Uncategorized

Source: CureToday articles First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma. Read More

Exploring a Patient Case: Biomarker Testing After Progression and Discussing Treatment Choices With Your Care Team

by MM360 Staff | May 5, 2025 | Uncategorized

Source: CureToday articles Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 and PIK3CA mutations. Read...

Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options

by MM360 Staff | May 5, 2025 | Uncategorized

Source: CureToday articles Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors. Read...
« Older Entries
Next Entries »

Recent Content

  • Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
  • The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
  • What Does Multiple Myeloma Mean?
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT